文献速递乳腺外科围术期管理与 ERAS

前瞻性多中心注册研究:靶向腋窝清扫在淋巴结阳性乳腺癌中的临床可行性

A Prospective, Multicenter Registry Study to Evaluate the Clinical Feasibility of Targeted Axillary Dissection (TAD) in Node-positive Breast Cancer Patients.
PubMed 文献 · Ann Surg · 2020-11-04

SenTa研究是在50个中心开展的前瞻性注册研究,纳入活检证实腋窝淋巴结阳性并放置标记夹的乳腺癌患者,评估新辅助全身治疗(NST)后靶向腋窝清扫(TAD)的可行性。NST后标记靶淋巴结术中切除率为77.8%(329/423,95%CI 74.0-82.0),TAD检出率为86.9%(199/229,95%CI 81.8-91.0),TAD后行腋窝淋巴结清扫的假阴性率为4.3%(2/46,95%CI 0.5-14.8)。

要点

  • NST后标记靶淋巴结术中切除率为77.8%,TAD检出率为86.9%。
  • TAD后行ALND的假阴性率为4.3%(2/46,95%CI 0.5-14.8)。
  • TLNB后行ALND的假阴性率为7.2%(8/111,95%CI 3.1-13.6)。

核心结论

  • SenTa研究表明TAD在真实世界乳腺癌患者队列中可行,对手术降阶梯策略有重要意义。

研究设计与样本

  • 前瞻性注册研究,在50个中心开展,纳入活检证实腋窝淋巴结阳性并放置标记夹的浸润性乳腺癌患者。
  • 2017至2018年间连续纳入548例患者,其中473例接受NST。

主要发现

  • NST后标记靶淋巴结术中切除率为77.8%(329/423,95%CI 74.0-82.0)。
  • TAD检出率为86.9%(199/229,95%CI 81.8-91.0),其中SLN与TLN一致者占64.8%(129例)。
  • TLNB后行ALND的假阴性率为7.2%(8/111,95%CI 3.1-13.6)。
  • TAD后行ALND的假阴性率为4.3%(2/46,95%CI 0.5-14.8)。

临床怎么用

  • 在真实世界临床实践中,对腋窝淋巴结阳性并放置标记夹的乳腺癌患者,NST后行TAD可行。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This study aimed to investigate the feasibility and accuracy of non-radioactive TLN biopsy and TAD in routine clinical practice. BACKGROUND DATA: TAD involves TLN biopsy (TLNB) and sentinel lymph node biopsy and was recently introduced as a new standard for less invasive axillary staging in BC patients undergoing neoadjuvant systemic therapy (NST); however, clinical evidence is limited. METHODS: The SenTa study is a prospective registry study conducted at 50 centers. Patients with invasive BC who nderwent clip insertion into the most suspicious axillary lymph node were eligible. Axillary surgery was performed with or without sentinel lymph node biopsy, TLNB, and/or axillary lymph node dissection (ALND). Main endpoints were the detection rate and FNR of TLNB and TAD after NST. RESULTS: Between 2017 and 2018, 548 consecutive BC patients underwent clip placement into biopsy-confirmed positive lymph nodes. After NST (n = 473), the clipped TLN was intraoperatively resected in 329 of 423 patients [77.8%, 95% confidence interval (CI): 74.0-82.0]. TAD was successful in 199 of 229 patients (detection rate: 86.9%, 95% CI: 81.8-91.0), the SLN and TLN were identical in 129 patient (64.8%). FNRs were 7.2% (8 of 111, 95% CI: 3.1-13.6) for TLNB followed by ALND (n = 203) and 4.3% (2 of 46, 95% CI: 0.5-14.8) for TAD followed by ALND (n = 77). CONCLUSIONS: The SenTa study demonstrates the feasibility of TAD in a real-world cohort of BC patients. Our findings are of great importance for de-escalation of surgical strategies.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Kuemmel S, Heil J, Rueland A, et al. A Prospective, Multicenter Registry Study to Evaluate the Clinical Feasibility of Targeted Axillary Dissection (TAD) in Node-positive Breast Cancer Patients. Ann Surg. 2020. PMID: 33156057. doi:10.1097/SLA.0000000000004572

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。